Getting Value from Nanotechnology in Healthcare (IEEE Spectrum)
In a white paper on drug delivery I contributed to writing a couple of years ago and in the accompanying report, we argued that one of the key economic drivers behind nanotechnology in drug delivery was unlocking the hidden value of many pharma companies’ already developed compounds.
This entry was posted
on Tuesday, March 2nd, 2010 at 8:08 pm and is filed under Nanotechnology.
You can follow any responses to this entry through the RSS 2.0 feed.
You can skip to the end and leave a response. Pinging is currently not allowed.